A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy

[1]  Christopher A. Lazarski,et al.  A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy , 2018, Cell Research.

[2]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[3]  K. Blenman,et al.  UV‐induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model , 2017, Pigment cell & melanoma research.

[4]  S. Carter,et al.  Loss of PTEN Is Associated with Resistance to Anti‐PD‐1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma , 2017, Immunity.

[5]  Jos Jonkers,et al.  Genetically engineered mouse models in oncology research and cancer medicine , 2016, EMBO molecular medicine.

[6]  J. Lunceford,et al.  Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  T. Graeber,et al.  Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells , 2016, Cancer Immunology Research.

[8]  M. Bosenberg,et al.  The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations , 2016, Pigment cell & melanoma research.

[9]  H. Kohrt,et al.  Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  T. Schumacher,et al.  Neoantigen landscape dynamics during human melanoma–T cell interactions , 2016, Nature.

[11]  J. Wargo,et al.  Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy , 2016, Current Oncology Reports.

[12]  J. Wolchok,et al.  Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. , 2016, JAMA.

[13]  L. Ferrucci,et al.  sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance , 2016, Nature.

[14]  J. McQuade,et al.  Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. , 2016, Cancer discovery.

[15]  Audrey Andrews.  Treating with Checkpoint Inhibitors-Figure $1 Million per Patient. , 2015, American health & drug benefits.

[16]  R. Rosell,et al.  Melanoma: oncogenic drivers and the immune system. , 2015, Annals of translational medicine.

[17]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[18]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[19]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[20]  C. Meyer,et al.  Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients , 2015, Proceedings of the National Academy of Sciences.

[21]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[22]  Michael R Stratton,et al.  High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma , 2014, Nature Medicine.

[23]  J. Utikal,et al.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.

[24]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[25]  N. Rosen,et al.  Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged. , 2014, Cancer cell.

[26]  Y. Kluger,et al.  PTEN functions as a melanoma tumor suppressor by promoting host immune response , 2014, Oncogene.

[27]  S. Rosenberg,et al.  Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions , 2014, Clinical Cancer Research.

[28]  Alexander M. Menzies,et al.  Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma , 2014, Clinical Cancer Research.

[29]  M. Stratton,et al.  Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[31]  A. Ribas,et al.  Targeting oncogenic drivers and the immune system in melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[33]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[34]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[35]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[36]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[37]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[38]  K. Flaherty,et al.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.

[39]  B. Kavanagh,et al.  CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. , 2008, Blood.

[40]  J. Bluestone,et al.  Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways , 2008, Immunological reviews.

[41]  E. Vadai,et al.  Exuberated numbers of tumor-specific T cells result in tumor escape. , 2008, Cancer research.

[42]  Kevin M Brindle,et al.  Monitoring T‐lymphocyte trafficking in tumors undergoing immune rejection , 2005, Magnetic resonance in medicine.

[43]  D. Brown,et al.  Tumours can act as adjuvants for humoral immunity , 2001, Immunology.

[44]  J. Wolchok,et al.  Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma , 2018, JAMA oncology.

[45]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.